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a  b s t r  a  c t
Secondary hyperparathyroidism (SHPT) is a  common complication in patients with chronic
kidney disease (CKD) that is characterised by elevated parathyroid hormone (PTH) levels
and a  series of bone-mineral metabolism anomalies. In patients with SHPT, treatment with
paricalcitol, a  selective vitamin D receptor activator, has been shown to reduce PTH levels
with minimal serum calcium and phosphorus variations. The classic effect of paricalcitol is
that  of a  mediator in mineral and bone homeostasis. However, recent studies have suggested
that the  benefits of treatment with paricalcitol go beyond PTH reduction and, for instance,
it  has a  positive effect on cardiovascular disease and survival. The objective of this study
is  to review the most significant studies on the  so-called pleiotropic effects of paricalcitol
treatment in patients with CKD.
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r e s u m e n
El hiperparatiroidismo secundario (HPTS) es una complicación habitual en pacientes con
enfermedad renal crónica que se caracteriza por unos niveles elevados de hormona
paratiroidea (PTH) y una serie de anomalías en el metabolismo mineral-óseo. En  pacientes
con  HPTS, el tratamiento con paricalcitol, un activador selectivo de  los receptores de la vita-
mina  D, ha demostrado reducir los niveles de PTH con mínimas variaciones del calcio y del
fósforo  séricos. El efecto clásico de  paricalcitol es el de  mediador en la homeostasis min-
eral  y  ósea. Sin  embargo, estudios recientes han indicado que los beneficios del tratamiento
con paricalcitol van más allá de la reducción de PTH, por ejemplo, ocasionando efectos
positivos en la enfermedad cardiovascular y  en la supervivencia. El objetivo del presente
trabajo es revisar los  estudios más significativos sobre los llamados efectos pleiotrópicos
del tratamiento con paricalcitol en pacientes con ERC.
© 2015 Sociedad Espan˜ola de  Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The classic physiological role of the vitamin D hormonal sys-
tem is in the essential regulation of bone mineral metabolism.
1,25-dihydroxyvitamin D3 binds with a  high affinity to vita-
min D receptors (VDR) and regulates serum levels of calcium
(Ca) and phosphorus (P) by increasing their absorption in
the intestine, increasing calcium reabsorption in  the renal
tubules, and suppressing secretion of parathyroid hormone
(PTH), which in turn is  a  key regulator of mineral metabolism.1
The decrease in 1,25-dihydroxyvitamin D3 levels is  attributed
to the increased production of FGF23 induced by the accu-
mulation of phosphate, which stimulates FGF23 production,
even without an evident increase in serum P concentra-
tion. Therefore, vitamin D deficiency plays a central role in
the development of secondary hyperparathyroidism (SHPT),
a common early complication in  patients with chronic kid-
ney disease (CKD)2–4 that progresses as  glomerular filtration
rate decreases.4 SHPT is characterised by high PTH levels and
the presence of bone and mineral abnormalities.1,2 SHPT and
abnormal mineral metabolism lead to  clinical consequences
at 2 levels: in the  musculoskeletal system and in the  cardio-
vascular system. The consequences in the musculoskeletal
system are due to increased bone remodelling, the most com-
mon  condition being osteitis fibrosa. The consequences on the
vascular system are related to the  increased risk of vascular
calcification.2
The usual treatment for SHPT involves dietary phospho-
rus restriction and drugs such as phosphate binders, VDR
activators (selective and non-selective), and/or calcimimetics
such as cinacalcet.2,3
The first commercial VDR activator (VDRA) was  calcitriol.2
Calcitriol is an important drug in the treatment of SHPT
in patients with CKD. However, due to its potent effects
on intestinal Ca and P absorption, this molecule frequently
induces hypercalcaemia, hyperphosphatemia, and renal cal-
culi formation, and increases the likelihood of calcification.
In 1998, paricalcitol was approved for the  treatment of
SHPT.5 This third-generation vitamin D analogue emerged in
view of the need for treatments that could inhibit high PTH
concentrations in  patients with SHPT, with a  minimal effect
on serum concentrations of Ca, P, and the calcium-phosphorus
product (Ca × P), without renal toxicity.4 Recently, paricalci-
tol has  been reclassified by the World Health Organisation to
H05BX (other antiparathyroid agents) rather than A11CC (vita-
min  D and analogues).
The beneficial effect of paricalcitol in reducing PTH levels
in patients with CKD is widely established.4 Its therapeutic
efficacy is due to the tissue selectivity of its mechanism of
action.4 Paricalcitol is  considered a  selective VDR activator.
The term “selective” refers to the  differential binding of the
ligand to the VDR. The synthesis of selective vitamin D recep-
tor  activators (sVDRA) such as  paricalcitol and maxacalcitol
came about because of the clinical need to broaden the thera-
peutic window of the classic vitamin D forms and to try to
reduce the risk of hypercalcaemia and hyperphosphatemia
associated with the non-selective derivatives calcitriol and
alfacalcidol. Selective VDRAs allow more  efficient inhibition
of PTH synthesis and secretion, with a  lesser effect on intesti-
nal absorption of calcium and phosphorus.6 The selectivity
of paricalcitol is explained at a biochemical level by the  C-
terminal of the vitamin D receptor, which is  the region that
binds specifically to the ligand.6
Although current clinical practice guidelines for CKD limit
the use of VDRAs to the treatment of SHPT,7 the VDR has been
identified in more  than 30 different human tissues (Table 1).8
This suggests the different actions that vitamin D may  have,
in addition to those related to bone and mineral homeostasis,
giving what are known as the “non-classical” effects of vitamin
D. Such effects include an anti-inflammatory immunomodu-
latory effect on cardiomyocyte remodelling,9 a  renal protective
effect, and to a lesser degree, an effect on the progression of
vascular remodelling, particularly in some derivatives.
The wide dissemination of VDRs in  human tissues explains
some potential effects in terms of improved cardiovascular
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Table 1 – Tissue distribution of vitamin D receptors.
System Tissue
Endocrine Parathyroid, pancreatic B cells, thyroid C
cells
Cardiovascular Arterial smooth muscle cells, cardiac
myocytes
Musculoskeletal Osteoblasts, chondrocytes, striated muscle
Gastrointestinal Oesophagus, stomach, intestine
Hepatic Liver parenchymal cells
Renal Tubules, juxtaglomerular apparatus (renin),
podocytes
Reproductive Testicles, ovaries, uterus
Immune T cells, B cells, bone marrow, thymus
Respiratory Alveolar cells of the  lung
Epidermis Keratinocytes, hair follicles
Central nervous
system
Neurons
structure and function, reducing the risk of cardiovascular
disease and mortality, particularly in patients with CKD.6
Paricalcitol  and  survival  in haemodialysis
patients
SHPT affects to, at least, half of all patients with end-stage
renal disease on dialysis10 and is associated with different
diseases and comorbidities, such as  increased risk of frac-
ture, vascular complications, and infections. Many of these
comorbidities may lead to hospital admission. Dobrez et  al.
observed that patients treated with paricalcitol had a  lower
risk of all-cause hospitalisation (–14%; P < .0001), fewer hospi-
talisations per year (–0.642; P  < .001), and fewer hospital days
per year (–6.84; P < .001) than patients treated with calcitriol.10
Furthermore, several epidemiological studies have shown
the significant systemic effect of VDR activation on survival,
in patients with SHPT on haemodialysis.5,11 The results of the
first study demonstrated that treatment with paricalcitol led
to a mortality rate that was  16%  lower than with the VDRA
calcitriol (95% CI).5 In that retrospective cohort study, the  dif-
ference in survival was  significant at 12 months of treatment
and increased over time (P < .001) (Figure 1a).5 Within that
study, there was one subgroup of patients that changed from
treatment with calcitriol to treatment with paricalcitol. At 2
years, that subgroup of patients had a higher survival rate than
the subgroup who changed from treatment with paricalcitol
to treatment with calcitriol (73% vs 64%, P < .04) (Figure 1b).5
The survival advantage for patients treated with paricalcitol
over those treated with calcitriol appears to be independent
of baseline serum levels of calcium, phosphorus, and PTH.5
In a  second retrospective study, patients who  received i.v.
vitamin D (calcitriol or paricalcitol) showed a  survival rate 20%
higher than those who did  not receive vitamin D (HR, 0.80; 95%
CI).11 Survival at 2  years was  75.6% in  the group of patients who
received vitamin D, vs 58.7% in the group of patients who  did
not receive vitamin D (P < .001).11 The survival advantage for
patients treated with i.v. vitamin D over with those not treated
with vitamin D also appears to  be independent of baseline
calcium, phosphate, and PTH levels (Figure 2).11
Another published study by Kalantar-Zadeh et  al. also asso-
ciated treatment with paricalcitol with improved survival, in
a cohort of patients on maintenance haemodialysis.12 The
authors observed that treatment with the vitamin D recep-
tor activator paricalcitol at any dose was  associated with
improved survival compared with those patients who  were not
treated with paricalcitol.12,13 Subsequently, Lee et al. compiled
the results of the  study by Kalantar-Zadeh et al. and similarly
demonstrated that the administration of paricalcitol at any
dose was associated with improved survival in subgroups of
patients on maintenance haemodialysis (Figure 3).13
Possible  mechanisms  to  explain  the  survival
benefit  associated  with  systemic  activation  of
vitamin  D  receptors
Vascular protection: paricalcitol in vascular calcification,
atherosclerosis, and cardiac structure and function.
Patients with stage 5 CKD on dialysis have a  high rate
of mortality due to cardiovascular complications.14–17 Several
studies have shown that vitamin D  deficit and activation of
the vitamin D receptor are associated with vascular calcifi-
cation and dysfunction and cardiovascular mortality, in both
the general population and in patients with CKD.1 Calcifica-
tion of vascular tissue is  common in  patients with CKD14,16
and has haemodynamic consequences, such as loss or arterial
elasticity, increased pulse wave velocity, development of left
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ventricular hypertrophy, reduced coronary artery perfusion,
myocardial ischaemia, and heart failure.17 This calcification
occurs at 2 distinct levels in the vessel: in the intimal layer,
were it is associated with atherosclerosis, and in the medial
layer, where it  is associated with arteriosclerosis due to factors
such as age, diabetes, and end-stage renal failure.14,17
The exact mechanisms responsible for the development
and progression of vascular calcification in patients with
CKD are not completely known.16 For many  years, it has
been proposed that vascular calcification is the result of a
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passive process, due to high phosphate levels and a  high
Ca × P  product.17 However, recent studies have shown a rela-
tionship between vascular calcification and osteogenesis,17
indicating that vascular calcification is  an  actively-regulated
process.17,18
Calcitriol and other vitamin D analogues are used for
the treatment of SHPT, but there is some disagreement
regarding whether or not these VDR activators directly
accelerate the vascular calcification process.17 For example,
in vitro and in  vivo studies have demonstrated that cal-
citriol induces calcification at high doses. However, other
VDRAs, such as paricalcitol, are less likely to cause hyper-
calcaemia and hyperphosphatemia or to induce vascular
calcification.16
VDRAs can have differential effects on vascular calci-
fication, and these effects are independent of the Ca ×  P
product,14,16 serum levels of Ca and P,14 and PTH.16 Unlike
paricalcitol, calcitriol15,16 and doxercalciferol14,16 appear to
increase aortic calcium content in studies with uraemic
post-nephrectomy rats. Even more  importantly, calcitriol and
doxercalciferol appear to increase the expression of Cbfa-1
(RunX-2), a  transcription factor that initiates the active mech-
anisms of vascular calcification.16
It is known that vascular smooth muscle  cells (VSMC)
have VDRs and contain the enzyme 25-hydroxyvitamin D3 1-
hydroxylase, indicating that vitamin D and its analogues play
an important role  in the function and physiology of this cell
type.17 In a study by Cardús et al., high doses of calcitriol, but
not of paricalcitol, increased calcification in VSMCs of post-
nephrectomy rats.18 The same study showed that treatment
Documento descargado de http://www.revistanefrologia.com el 13/10/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.
14  n e f r  o l  o g i  a. 2  0 1  6;3 6(1):10–18
with hypercalcaemiant doses of calcitriol increased pulse
pressure (the difference between systolic arterial pressure and
diastolic arterial pressure), probably due to the extensive arte-
rial calcification observed. In contrast, in rats treated with
paricalcitol, no increase was observed in aortic calcification
or pulse pressure.18
Noonan et  al. quantified the functional consequences of
vascular calcification and observed that paricalcitol had no
effects on pulse wave velocity, whereas high doses of doxer-
calciferol increased pulse wave  velocity in  post-nephrectomy
rats at 6 weeks of study.
While the activation of VDRs can slow vascular calci-
fication in induced uraemia, recent data also support the
role of VDR activation in the prevention or slowing of
atherosclerosis.8 VDRAs have shown a beneficial effect on
thrombosis, inflammation, and vasodilatation, risk factors
associated with endothelial function and the atherosclerotic
process.19 According to a study performed in  primary cultures
of human aortic smooth muscle cells, VDRs may  play a role in
atherosclerosis by regulating plasminogen activator inhibitor-
1, thrombospondin-1, and thrombomodulin. Thus, VDRs could
contribute to the  therapeutic benefit that vitamin D analogues
have in reducing morbidity and mortality risk in patients with
stage 5 CKD.20
A subsequent study assessed the protector effect of par-
icalcitol, an angiotensin-converting enzyme inhibitor (ACEI)
(enalapril), and a  combination of both, on oxidative dam-
age in atherosclerotic mice aortas.21 In the study, paricalcitol
alone, enalapril alone, and a  combination of paricalcitol
plus enalapril all prevented atherosclerotic plaque forma-
tion in ApoE21-deficient mice and showed a protector effect
against cardiac oxidative stress in uraemia.22 This pro-
tection against the  inflammation and oxidative damage
of atherosclerosis was greater with the combined ther-
apy (enalapril + paricalcitol) than with monotherapy.21 In the
results of the study, it  was  observed that both paricalcitol
and enalapril as monotherapies, as  well as the combination
of the two, reduced the concentration of the enzyme aortic
malondialdehyde (MDA)  and increased levels of the enzyme
glutathione peroxidase (GSH-Px).21 Both the reduction of MDA
levels and the increase in  GSH-Px levels are indicative of the
protector effect of paricalcitol, enalapril, and the combination
of both, in this model of atherosclerotic mice.21 In addition,
paricalcitol also appears to improve endothelial function in
uraemic rats in a dose-dependent manner and independently
of PTH levels and blood pressure.19
In addition, it  is thought that paricalcitol is  associated with
a lower cardiovascular morbidity, possibly due to modification
of cardiac structure and function.23,24 The PRIMO study dealt
with determining the effects of paricalcitol on left ventricular
mass over a period of 48 weeks in patients with CKD and left
ventricular hypertrophy.23,24 During the study period, parical-
citol did not reduce left ventricular mass or  improve certain
Doppler measurements of diastolic function, but it did appear
to be associated with fewer hospitalisations for cardiovascu-
lar causes.23 In a  post hoc analysis of the PRIMO study, there
was a significant reduction in  left ventricular volume index in
the group of patients treated with paricalcitol compared with
those in the placebo group (P  = .002).24
Renal  protection:  reduction  of  proteinuria  and  renal
fibrosis
Several studies have demonstrated the renoprotective effect
of vitamin D analogues in experimental animal models with
glomerular disease.25
Diabetic nephropathy, which is characterised by glomeru-
lar lesions, inflammatory infiltration, tubular atrophy, and
interstitial fibrosis,26 is one of the most complex renal diseases
and is often associated with cardiovascular complications.
Tubulointerstitial damage or fibrosis in CKD leads to end-stage
renal failure.27 In a mouse model with interstitial obstructive
nephropathy due to unilateral ureteric ligation,27 parical-
citol reduced interstitial inflammation and the production
and accumulation of interstitial matrix components (colla-
gen and fibronectin). In this model, paricalcitol also inhibited
the transition of epithelial cells to mesenchymal cells, a
process that is partly responsible for renal fibrosis.27 In addi-
tion, paricalcitol restored the number of VDRs in obstructive
nephropathy.27 Paricalcitol also blocked in  vitro and in  vivo
expression of the Snail gene, Snail being a  transcription factor
that plays a  crucial role in initiating epithelial to mesenchy-
mal  transition. These results indicate that the beneficial effect
of paricalcitol is  associated with its capacity to preserve
the tubular epithelial phenotype by suppressing transition.27
Likewise, paricalcitol has a beneficial inhibitory effect on
renal inflammation thanks to signalling-sequestration of
nuclear transcription factors such as nuclear factor kappa B
(NF-KB).26
The urinary protein/albumin ratio is an  important marker
of renal and cardiovascular disease28,29 that is associated
with CKD progression.1 Increased urinary protein reflects a
higher degree of glomerular disease or underlying renal tubu-
lar dysfunction,1 and plays a  direct role  in  progression of renal
and cardiovascular disease.1,28,29
The renin–angiotensin–aldosterone system (RAAS) has
been identified as an  important mediator of progressive
renal damage in diabetic nephropathy. The drugs that affect
the RAAS, such as ACEIs and angiotensin receptor block-
ers (ARBs), can delay cardiovascular and renal morbidity and
mortality.30 However, residual proteinuria may be high in
patients that receive these treatments1;  therefore, different
treatment strategies are needed to reduce that residual risk.1
Recent studies have shown that the selective activation of
VDRs could be of relevance in the reducing proteinuria in
patients with CKD.29
In a post hoc analysis of a randomised trial that assessed
the efficacy of oral paricalcitol in reducing PTH in patients
with CKD,3,4 a reduction in proteinuria was observed in
more  than 50% of the patients treated with paricalcitol.
This reduction was independent of concomitant treatment
with RAAS inhibitors (P = .004).28 In another randomised
double-blind study, paricalcitol significantly reduced protein
excretion measured by the  urinary protein-creatinine ratio at
baseline and at the end of the study in 2 groups of patients:
one treated with paricalcitol and the other with placebo.29
In one short study, 24 patients were randomly assigned to
receive placebo, 1  g of paricalcitol, or 2 g  of paricalcitol.
Following evaluation, a  reduction in proteinuria was observed
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in patients on paricalcitol, independently of haemodynamic
changes or  reduction in PTH levels.31
The VITAL study showed that treatment for 24 weeks with
2 g of paricalcitol reduced residual albuminuria in patients
with type 2 diabetes mellitus and kidney disease that were
being treated with stable doses of ACEIs or ARBs.30 The change
in the urinary albumin-creatinine ratio (UACR) from baseline
level to the end of treatment was greater in the  groups of
patients treated with paricalcitol (1 or 2  g) than in the placebo
group (P =  .071). Fig. 4  shows how the differences in UACR
appeared to have a  dose-response relationship with the use of
paricalcitol, indicating that paricalcitol could be an important
adjuvant treatment in the reduction of residual albuminuria.30
A recently-published meta-analysis of 9 studies (n = 832)
by Cheng et al. confirmed the beneficial effect of paricalci-
tol in reducing proteinuria (P  = .001) without increased risk of
adverse effects.32
Paricalcitol  as  an  immunomodulatory  and
anti-inflammatory  agent
Several epidemiological studies have associated vitamin
D deficiency with an  increased susceptibility to  immune-
mediated diseases, including chronic infections and auto-
immune diseases.33 Systemic inflammatory processes are
common in patients with CKD and constitute a  marker of
poor prognosis.1 It is also known that immune cells express
vitamin D activator enzymes, allowing local conversion of
inactive vitamin D to  its active form 1,25(OH)(2)D(3).33 These
data indicate that vitamin D plays a  role in maintaining
immune homeostasis.33 Several studies have evaluated the
immunomodulatory effect of paricalcitol and other VDRAs in
this area.25,30,33
Paricalcitol and calcitriol have been demonstrated to
reduce differentiation of immature dendritic cells from
monocytes and their activation capacity.25 The preven-
tion of dendritic cell maturation may  play an important
role in the prevention of autoimmune diseases, including
atherosclerosis.25 The immunomodulatory action of vitamin
D also occurs through regulation of the activity of differ-
ent types of immune cells, such as  macrophages, dendritic
cells, and T cells,33,34 and regulation of expression of the pro-
inflammatory cytokines RANTES and TNF-.34
Tan et al. also observed a beneficial effect from paricalcitol
on the inhibition of renal inflammation, due to seques-
tration of NF-KB signalling.34 Another short, randomised
double-blind study in patients with CKD showed a  signifi-
cant reduction of serum concentration of C-reactive protein
(CRP), measured using a high-sensitivity method.31 Likewise,
paricalcitol was associated with inflammation modulation
in patients on haemodialysis by a reduction in inflam-
matory biomarkers such as CRP and TNF- and improved
IL-6/IL-10 and TNF-/IL-10 ratios.35 These anti-inflammatory
effects of paricalcitol were independent of iPTH concentration
(Figure 5).35
In another recently published study by Sánchez-Nin˜o  et al.,
an  anti-inflammatory effect was observed for both paricalci-
tol and calcitriol in  an  experimental model using rats with
streptomycin-induced diabetes. Calcitriol and paricalcitol
reduced the expression of the anti-inflammatory mediators
fibronectin and renin in cultivated podocytes. These VDRAs
reduced glomerular inflammation even at sub-antiproteinuric
doses.36
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Importance  of  paricalcitol  in  transplant  patients
A normal-functioning renal transplant corrects the endocrine
and metabolic imbalances secondary to renal function
deterioration.37,38 However, after renal transplant, persistent
elevation of PTH is observed in a  considerable percentage
of patients. Whilst it usually returns to  normal slowly in
patients with normal graft function, in patients with mild or
moderate deterioration of renal function it can persist indef-
initely. The persistence of high PTH is a risk factor for loss
of bone mass and increased risk of fracture. Reduced bone
mineral density has also been associated with an  increased
risk of atherosclerosis.39 Therefore, better control of PTH may
improve both aspects.
Furthermore, several studies have shown that at one
year post-transplant, proteinuria is present in up to 45% of
patients; in  two  thirds of these patients, the level is  below
500 mg/day.40,41 Proteinuria is one of the factors that signifi-
cantly predisposes to reduced renal graft survival.42
As there is a  certain degree of similarity between chronic
graft disease and chronic kidney disease, is can be assumed,
logically, that antiproteinuric therapeutic approaches could be
beneficial in renal transplant patients.43,44 As  has been seen
throughout this review, in patients with CKD, paricalcitol has
been shown to  be capable of reducing proteinuria in both
patients with SHPT and those with normal PTH levels.
Experience with paricalcitol in renal transplant patients is
limited; however, in the few studies that have been published,
paricalcitol appears to have been effective in  improving con-
trol of PTH and proteinuria in this group of patients.
In a retrospective study that included 58  renal transplant
patients with secondary hyperparathyroidism, treatment with
paricalcitol significantly reduced serum iPTH levels and pro-
teinuria (35% decrease relative to baseline levels). Renal
function remained stable during treatment with paricalcitol,
with a significant difference compared with the  deteriora-
tion observed in the 2 years prior to treatment.45 In another,
prospective study in a  population of 46 transplant patients
that assessed urinary peptidome, treatment with 1 g/day of
paricalcitol for 3 months effectively reduced PTH levels and
notably modified the urinary peptide profile.37 In another
study, published only as an abstract, that compared the
use of different vitamin D analogues in  patients with renal
transplant, treatment with paricalcitol was  associated with a
greater reduction in proteinuria.46
Toxicity from calcineurin inhibitors is one of the most
significant causes of chronic graft disease. At an experimen-
tal level, it has  been observed that paricalcitol attenuates
cyclosporine-induced nephropathy, suppressing interstitial
inflammation and fibrosis and epithelial tubule cell fibrosis.47
This could be,  therefore, an  additional beneficial effect
of paricalcitol in renal transplant patients on calcineurin
inhibitors.
Conclusions
Paricalcitol, a third-generation VDRA, provides effective
control of SHPT with minimal hypercalcaemic and hyper-
phosphatemic effects.4 Its therapeutic efficacy is  due to the
tissue selectivity of its mechanism of action, as it does not up-
regulate the intestinal vitamin D receptor and is less active
than calcitriol at a bone level.4
Recent studies have indicated that the benefits of parical-
citol go beyond the reduction of PTH and bone and mineral
homeostatic control. This review shows that the pleiotropic
effects of paricalcitol on cardiovascular structure and func-
tion, proteinuria, and immune function, amongst others,1,8,9
may  explain the increased survival rate observed in patients
with CKD treated with paricalcitol.5
Although more  experience is needed, use of paricalcitol in
renal transplant patients appears to be a  safe and promising
option for improving control of high PHT levels and protein-
uria.
Conflicts  of  interest
The authors declare the following potential conflicts of inter-
est:
Dr Jordi Bover has given talks sponsored by Abbott (Abb-
vie), Amgen, Genzyme, and Shire. He has also participated
in  national and international advisory committees for Abbott
(Abbvie), Amgen, and Genzyme.
Dr Alberto Martínez has received research grants and has
given talks sponsored by Abbott (Abbvie), Amgen, Boëhringer-
Ingelheim, Esteve, Janssen-Cilag, Novartis, Roche, and Shire.
He has also participated in  advisory boards for Abbott (Abbvie),
Amgen, Esteve, Roche, and Shire.
Dr Egido has performed work as  scientific advisor, and
has  received research funding and given takks sponsored by
Abbott (Abbvie).
Dr Elvira Fernandez-Giraldez has received research funding
and has  given talks sponsored by Abbott (Abbvie).
Dr Carlos Solozabal has given talks sponsored by Abbott
(Abbvie).
r  e  f  e  r  e n c e  s
1. Gravellone L,  Rizzo MA, Martina V, Mezzina N, Regalia A,
Gallieni M. Vitamin D receptor activators and clinical
outcomes in chronic kidney disease. Int J  Nephrol.
2011;2011:419524.
2. Hervás Sánchez JG, Prados Garrido MD, Polo Moyano A,
Cerezo Morales S. Efectividad del tratamiento con paricalcitol
por  vía oral en pacientes con enfermedad renal crónica en
etapas anteriores a  la diálisis. Nefrología. 2011;31:697–706.
3. Brancaccio D, Bommer J, Coyne D.  Vitamin D receptor
activator selectivity in the treatment of secondary
hyperparathyroidism. Understanding the  differences among
therapies. Drugs. 2007;67:1981–98.
4. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S,
et al. Paricalcitol en cápsulas para el tratamiento del
hiperparatiroidismo secundario de enfermedad renal crónica
en estadios 3 y  4. Am J  Kidney Dis. 2006;47:263–76.
5. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM,  Thadhani R.
Survival of patients undergoing hemodialysis with
paricalcitol or  calcitriol therapy. N  Engl J Med.
2003;349:446–56.
6. Cozzolino M, Bruschetta E, Stucchi A,  Ronco C, Cusi D. Role of
vitamin D receptor activators in cardio-renal syndromes.
Semin Nephrol. 2012;32:63–9.
Documento descargado de http://www.revistanefrologia.com el 13/10/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.
n e f r  o l  o g i  a. 2 0 1 6;3 6(1):10–18 17
7. Kidney Disease: Improving Global Outcomes (KDIGO)
CKD-MBD Work Group. KDIGO clinical practice guideline for
the diagnosis, evaluation, prevention, and treatment of
Chronic Kidney Disease-Mineral and Bone Disorder
(CKD-MBD). Kidney Int Suppl. 2009;113:S1–130.
8. Andress DL. Vitamin D in chronic kidney disease: a  systemic
role  for selective vitamin D receptor activation. Kidney Int.
2006;69:33–43.
9. Valdivielso JM, Cannata-Andía J, Coll B, Fernández E. A  new
role  for vitamin D receptor activation in chronic kidney
disease. Am J  Physiol Renal Physiol. 2009;297:F1502–9.
10. Dobrez DG, Mathes A,  Amdahl M, Marx SE, Melnick JZ,
Sprague SM. Paricalcitol-treated patients experience
improved hospitalization outcomes compared with
calcitriol-treated patients in real-world clinical settings.
Nephrol Dial Transpl. 2004;19:1174–81.
11. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, et al.
Activated injectable vitamin D and hemodialysis survival: a
historical cohort study. J Am Soc Nephrol. 2005;16:
1115–25.
12. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP,
Kilpatrick RD, et al.  Survival predictability of time-varying
indicators of bone disease in maintenance hemodialysis
patients. Kidney Int. 2006;70:771–80.
13. Lee GH, Benner D, Regidor DL, Kalantar-Zadeh K. Impact of
kidney  bone disease and its  management on survival of
patients on dialysis. J  Ren Nutr. 2007;17:38–44.
14. Noonan W,  Koch K, Nakane M, Ma J, Dixon D, et al.
Differential effects of vitamin D receptor activators on aortic
calcification and pulse wave velocity in uraemic rats. Nephrol
Dial Transpl. 2008;12:3824–30.
15. Wu-Wong JR, Noonan W, Ma J,  Dixon D, Nakane M, et al. Role
of  phosphorus and vitamin D analogs in the pathogenesis of
vascular calcification. J Pharmacol Exp Ther. 2006;318:
90–8.
16. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential
effects of vitamin D receptor activators on vascular
calcification in uremic rats. Kidney Int. 2007;72:709–15.
17. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification:
the killer of patients with chronic kidney disease. Am Soc
Nephrol. 2009;20:1453–64.
18. Cardús A, Panizo S, Parisi E, Fernández E, Valdivielso JM.
Differential effects of vitamin D analogs on vascular
calcification. J  Bone Miner Res. 2007;22:860–6.
19. Wu-Wong JR, Noonan W, Nakane M, Brooks KA, Segreti JA,
Polakowski JS, et al. Vitamin d receptor activation mitigates
the impact of uremia on endothelial function in the  5/6
nephrectomized rats. Int J Endocrinol. 2010;2010:625852.
20. Wu-Wong JR, Nakane M, Ma J. Vitamin D analogs modulate
the expression of plasminogen activator inhibitor-1,
thrombospondin-1 and thrombomodulin in human aortic
smooth muscle cells. J  Vasc Res. 2007;44:11–8.
21. Husain K, Suarez E, Isidro A, Ferder L. Effects of paricalcitol
and  enalapril on atherosclerotic injury in mouse aortas. Am J
Nephrol. 2010;32:296–304.
22. Husain K, Ferder L, Mizobuchi M, Finch J,  Slatopolsky E.
Combination therapy with paricalcitol and enalapril
ameliorates cardiac oxidative injury in uremic rats. Am J
Nephrol. 2009;29:465–72.
23. Malluche HH, Mawad H, Koszewski NJ. Update on vitamin D
and  its newer analogues: actions and rationale for treatment
in  chronic renal failure. Kidney Int. 2002;62:367–74.
24. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation
by promoting vitamin D receptor-mediated sequestration of
NF-KB signaling. J  Am Soc Nephrol. 2008;19:1741–52.
25. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial
fibrosis in obstructive nephropathy. J Am Soc Nephrol.
2006;17:382–393.
26. Agrawal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu
P, et al. Antiproteinuric effect of oral paricalcitol in chronic
kidney disease. Kidney Int. 2005;68:2823–8.
27. Fishbane S, Chittineni H, Packman M,  Dutka P, Ali N, Durie N.
Oral paricalcitol in the treatment of patients with CKD and
proteinuria: a  randomized trial. Am J  Kidney Dis.
2009;54:647–52.
28. De  Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D,
Garimella T, et al. Selective vitamin D receptor activation with
paricalcitol for reduction of albuminuria in patients with type
2  diabetes (VITAL study): a  randomised controlled trial.
Lancet. 2010;376:1543–51.
29. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM,  et al.
Paricalcitol reduces albuminuria and inflammation in chronic
kidney disease. a  randomized double-blind pilot trial.
Hypertension. 2008;52:249–55.
30. Cheng J, Zhang W, Zhang X, Li X, Chen J. Efficacy and safety of
paricalcitol therapy for chronic kidney disease: a
meta-analysis. Clin J Am Soc Nephrol. 2012;7:391–400.
31. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin
D:  modulator of the  immune system. Curr Opin Pharmacol.
2010;10:482–96.
32. Schorová K, Budinsky´  V, Rozˇková D, Tobiasová Z,
Dusilová-Sulková S, Spísek R, et al. Paricalcitol
(19-nor-1,25-dihydroxyvitamin D2) and calcitriol
(1,25-dihydroxyvitamin D3) exert potent immunomodulatory
effects on dendritic cells and inhibit induction of
antigen-specific T cells. Clin Immunol. 2009;133:69–77.
33. Navarro-González JF, Méndez ML, Mora C, Muros M,  Gallego E,
et  al. Oral paricalcitol improves inflammatory profile in
haemodialysis patients. Póster presentado en el Congreso de
la ISN en Vancouver; 2011.
34.  Sánchez-Nin˜o MD, Bozic M, Córdoba-Lanús E, Valcheva P,
Gracia O, Ibarz M, et al. Beyond proteinuria: VDR activation
reduces renal inflammation in experimental diabetic
nephropathy. Am J  Physiol Renal Physiol. 2012;302:F647–57.
35. Pérez V, Sánchez A, Bayés B, Navarro-Mun˜oz M, Lauzurica R,
et  al. Effect of paricalcitol on the urinary peptidome of kidney
transplant patients. Transplant Proc. 2010;42:2924–7.
36. Bonarek H, Merville P, Bonarek M, Moreau K, Morel D, Aparicio
M, et al. Reduced parathyroid functional mass after
successful kidney transplantation. Kidney Int. 1999;56:642–9.
37. Oschatz E, Benesch T, Kodras K, Hoffmann U, Haas M.
Changes of coronary calcification after kidney
transplantation. Am J Kidney Dis. 2006;48(2):307–13.
38. Amer H, Cosio FG. Significance and management of
proteinuria in kidney transplant recipients. J Am Soc Nephrol.
2009;20:2490–2.
39. Amer H, Filder ME, Myslak M, Morales P, Kremers WK, Larson
TS, et al. Proteinuria after kidney transplantation,
relationship to allograft histology and survival. Am J  Transpl.
2007;7:2748–56.
40. Fernández-Fresnedo G,  Plaza JJ, Sánchez-Plumed J,
Sanz-Guajardo A,  Palomar-Fontanet R, Arias M. Proteinuria: a
new marker of long-term graft and patient survival in kidney
transplantation. Nephrol Dial Transpl. 2004;19:iii47–51.
41. Soler MJ, Riera M, Gutiérrez A, Pascual J. New options and
perspectives for proteinuria management after kidney
transplantation. Transpl Rev (Orlando). 2012;26(1):44–52.
42. Ruiz JC, Sánchez-Fructuoso A, Zárraga S.  Management of
proteinuria in clinical practice after kidney transplantation.
Transpl Rev (Orlando). 2012;26(1):36–43.
43. Gonzalez E, Rojas-Rivera J, Polanco N, Morales E, Morales JM,
Egido J,  et al. Effects of oral paricalcitol on secondary
hyperparathyroidism and proteinuria of kidney transplant
patients. Transplantation. 2013;95:e49–52.
44. Palya A,  Noor F,  Vania S, Kumar M, Ranganna K, Ahmed Z.
Vitamin D analogues reduce proteinuria in kidney
Documento descargado de http://www.revistanefrologia.com el 13/10/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.
18  n e f r  o l  o g i  a. 2  0 1  6;3 6(1):10–18
transplant (KTx) patients. Am J Transpl. 2009;9 Suppl. 2:
189–729.
45. Park JW,  Bae EH, Kim IJ, Ma SK, Choi C,  Lee J, et al. Paricalcitol
attenuates cyclosporine-induced kidney injury in rats. Kidney
Int.  2010;77(12):1076–85.
46. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J,
Tamez H, et al. Vitamin D therapy and cardiac structure and
function in patients with chronic kidney disease. JAMA.
2012;307(7):674–84.
47. Tamez H, Zoccali C, Packham D, Wenger J, Bhan I,  Appelbaum
E, et al. Vitamin D reduces left atrial volume in patients with
left  ventricular hypertrophy and chronic kidney disease. Am.
Heart J. 2012;164:902–9.
Documento descargado de http://www.revistanefrologia.com el 13/10/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.
